ArticleSignal transduction and targeted therapy2025
Neutralizing antibody durability and SARS-CoV-2 infection in older adults six months after XBB-containing vaccine booster.
Article in Signal transduction and targeted therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Booster mRNA Vaccination Prevents Breakthrough Severe COVID-19 Infections.Journal of medical virology · 2026Article
- Adapting covid-19 vaccination through targeted approaches: FDA-approved vaccines for the 2025-2026 season.Immunologic research · 2026Review
- Aging and vaccines: impact of immunosenescence and inflammaging in vaccine response.Frontiers in aging · 2026Review
- Comparative immunogenicity of COVID-19 vaccination in pregnant and non-pregnant women: a real-world cohort study.Frontiers in public health · 2026Article
- The virology of Omicron: pathophysiology, immune regulation, and clinical impact of SARS-CoV-2 sub variants.Virology journal · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
The persistence of XBB-containing vaccine-induced immunity against evolving SARS-CoV-2 variants remains uncertain, particularly in older adults, who are at increased risk of severe outcomes and may experience more rapid immune decline. We previously reported neutralizing antibody (nAb) responses 21 days after a single booster dose of trivalent XBB.1.5 (Tri‑XBB.1.5), bivalent Omicron XBB (Bi‑Omi‑XBB), or tetravalent XBB.1 (Tetra‑XBB.1) vaccines in a cohort of 90 older adults aged >65 years. In this six-month longitudinal follow-up analysis of the same cohort, we assessed nAb durability and SARS-CoV-2 infections to extend our earlier findings. Six months post-vaccination, the nAb titers decreased over time, with 2.5‒4.6-fold reductions in the geometric mean titer against the variants KP.3.1.1 and XEC; however, the nAb titer remained detectable in most participants. The Tri‑XBB.1.5 vaccine exhibited marginally better antibody persistence than the Bi‑Omi‑XBB and Tetra‑XBB.1 vaccines did, suggesting potential formulation-dependent differences in long-term immunogenicity. Twenty-seven participants experienced SARS-CoV-2 infection, including 11 (12.2%) confirmed by rapid antigen testing and 16 (17.8%) classified as probably based on serological evidence, with relatively frequent infections in bivalent and tetravalent recipients. Lower nAb titers on day 21 were linked to early infections, whereas late infections reflected antibody waning. Infections transiently increased nAb levels, but the elevated titers were not sustained. These findings highlight the importance of updating booster formulations and improving vaccine designs to address emerging immune-evasive variants.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.